Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects
ConclusionsUstekinumab pharmacokinetics are generally comparable across all approved inflammatory-mediated indications and healthy subjects after accounting for the body weight-related pharmacokinetic difference.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Clinical Trials | Crohn's Disease | Drugs & Pharmacology | Inflammatory Bowel Disease | Psoriasis | Psoriatic Arthritis | Rheumatology | Stelara | Study | Ulcerative Colitis